Department of Neurology, Tampere University Hospital, Tampere, Finland.
Department of Neurological Sciences, University of Helsinki, Helsinki, Finland.
Sleep. 2019 Mar 1;42(3). doi: 10.1093/sleep/zsy238.
To validate Ullanlinna Narcolepsy Scale (UNS) as a screening tool for narcolepsy in a clinical population and to compare it with Swiss Narcolepsy Scale (SNS) and Epworth Sleepiness Scale (ESS).
UNS questionnaires of 267 participants visiting Helsinki Sleep Clinic were analyzed. The diagnoses of the participants were narcolepsy type 1 (NT1, n = 89), narcolepsy type 2 (NT2, n = 10), other hypersomnias (n = 24), sleep apnea (n = 37), restless legs syndrome or periodic limb movement disorder (n = 56), and other sleep-related disorders (n = 51). In addition, ESS and SNS scores in a subset of sample (total N = 167) were analyzed and compared to UNS.
Mean UNS score in NT1 was 22.0 (95% confidence interval [CI] = 20.4 to 23.6, range 9-43), which was significantly higher than in other disorders, including NT2 (mean 13.7, 95% CI = 10.3 to 17.1, range 7-21, p = .0013). Sensitivity and specificity of UNS in separating NT1 from other disorders were 83.5% and 84.1%, respectively. Positive and negative predictive values were 82.5% and 85.1%, respectively. Sensitivities of SNS and ESS in NT1 were 77.2% and 88.6%, and specificities 88.6% and 45.5%, respectively. There were no differences in receiver operating characteristic curves between UNS and SNS. UNS had moderate negative correlation with hypocretin-1 levels (rs = -.564, p < .001), and mean sleep latency in multiple sleep latency test (rs= -.608, p < .001).
UNS has high specificity and sensitivity for NT1 in a sleep clinic setting. UNS scores below 9 strongly suggest against the diagnosis of narcolepsy.
验证 Ullanlinna 嗜睡量表(UNS)作为嗜睡症的筛查工具在临床人群中的有效性,并将其与瑞士嗜睡量表(SNS)和 Epworth 嗜睡量表(ESS)进行比较。
对访问赫尔辛基睡眠诊所的 267 名参与者的 UNS 问卷进行了分析。参与者的诊断为 1 型发作性睡病(NT1,n=89)、2 型发作性睡病(NT2,n=10)、其他嗜睡症(n=24)、睡眠呼吸暂停(n=37)、不宁腿综合征或周期性肢体运动障碍(n=56)和其他与睡眠相关的障碍(n=51)。此外,对样本中的一小部分(共 N=167)进行了 ESS 和 SNS 评分分析,并与 UNS 进行了比较。
NT1 组的平均 UNS 评分为 22.0(95%置信区间[CI]为 20.4 至 23.6,范围 9 至 43),显著高于其他疾病,包括 NT2(平均 13.7,95%CI 为 10.3 至 17.1,范围 7 至 21,p=.0013)。UNS 区分 NT1 与其他疾病的灵敏度和特异性分别为 83.5%和 84.1%。阳性和阴性预测值分别为 82.5%和 85.1%。SNS 和 ESS 在 NT1 中的灵敏度分别为 77.2%和 88.6%,特异性分别为 88.6%和 45.5%。UNS 和 SNS 的受试者工作特征曲线无差异。UNS 与下丘脑泌素-1 水平呈中度负相关(rs=-.564,p<.001),与多次睡眠潜伏期试验中的平均睡眠潜伏期呈中度负相关(rs=-.608,p<.001)。
在睡眠诊所环境中,UNS 对 NT1 具有高特异性和灵敏度。UNS 评分低于 9 强烈提示排除嗜睡症诊断。